The homophilic domain - An immunological archetype

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Kohler, Heinz ^a   Bayry, Jagadeesh ^b,c,d   Kaveri, Srinivas V ^b,c,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

1F7; Homophilic; Idiotype; Immunoglobulins; Induced antibodies; Natural antibodies; T15

Indexed keywords

EID: 84964647487     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00106     Document Type: Short Survey

References (66)

1. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today (1991) 12(5):154-9. doi: 10.1016/S0167-5699(05)80045-3.
2. Kohler H, Bayry J, Nicoletti A, Kaveri SV. Natural autoantibodies as tools to predict the outcome of immune response? Scand J Immunol (2003) 58(3):285-9. doi:10.1046/j.1365-3083.2003.01314.x.
3. Elluru SR, Vani J, Delignat S, Bloch MF, Lacroix-Desmazes S, Kazatchkine MD, et al. Modulation of human dendritic cell maturation and function by natural IgG antibodies. Autoimmun Rev (2008) 7(6):487-90. doi:10.1016/j.autrev.2008.04.014.
4. Kaveri SV, Silverman GJ, Bayry J. Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol (2012) 188(3):939-45. doi:10.4049/jimmunol.1102107.
5. Elluru SR, Kaveri SV, Bayry J. The protective role of immunoglobulins in fungal infections and inflammation. Semin Immunopathol (2015) 37(2):187-97. doi:10.1007/s00281-014-0466-0.
6. Cunningham AF, Flores-Langarica A, Bobat S, Dominguez Medina CC, Cook CN, Ross EA, et al. B1b cells recognize protective antigens after natural infection and vaccination. Front Immunol (2014) 5:535. doi:10.3389/fimmu.2014.00535.
7. Sidman CL, Shultz LD, Hardy RR, Hayakawa K, Herzenberg LA. Production of immunoglobulin isotypes by Ly-1+ B cells in viable motheaten and normal mice. Science (1986) 232(4756):1423-5. doi:10.1126/science.3487115.
8. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol (2011) 11(1):34-46. doi:10.1038/nri2901.
9. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med (2011) 208(1):67-80. doi:10.1084/jem.20101499.
10. Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev (2008) 7(6):440-4. doi:10.1016/j.autrev.2008.04.011.
11. Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S. Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles. Blood (2013) 121(11):2013-28. doi:10.1182/blood-2012-08-447771.
12. Bouhlal H, Martinvalet D, Teillaud JL, Fridman C, Kazatchkine MD, Bayry J, et al. Natural autoantibodies to Fcgamma receptors in intravenous immunoglobulins. J Clin Immunol (2014) 34(Suppl 1):S4-11. doi:10.1007/s10875-014-0019-2.
13. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med (2012) 367(21):2015-25. doi:10.1056/NEJMra1009433.
14. Bayry J, Hartung HP, Kaveri SV. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends Pharmacol Sci (2015) 36(7):419-21. doi:10.1016/j.tips.2015.04.012.
15. Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ (2015) 187(4):257-64. doi:10.1503/cmaj.130375.
16. Cantarini L, Rigante D, Vitale A, Napodano S, Sakkas LI, Bogdanos DP, et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res (2015) 61(3):326-37. doi:10.1007/s12026-014-8615-z.
17. Lunemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology - mode of action and clinical efficacy. Nat Rev Neurol (2015) 11(2):80-9. doi:10.1038/nrneurol.2014.253.
18. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol (2012) 30:221-41. doi:10.1146/annurev-immunol-020711-074934.
19. Maddur MS, Kaveri SV, Bayry J. Regulation of human dendritic cells by B cells depends on the signals they receive. Blood (2012) 119(16):3863-4. doi:10.1182/blood-2012-02-408948.
20. Morva A, Lemoine S, Achour A, Pers JO, Youinou P, Jamin C. Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood (2012) 119(1):106-14. doi:10.1182/blood-2011-06-360768.
21. Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, et al. Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nat Commun (2014) 5:4092. doi:10.1038/ncomms5092.
22. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med (2000) 192(4):475-82. doi:10.1084/jem.192.4.475.
23. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) (1974) 125C:373-89.
24. Oudin J. [The idiotyping of antibodies]. Ann Immunol (Paris) (1974) 125C:309-37.
25. Cazenave PA, Oudin J. [Idiotype of antibodies, in the serum of rabbits immunized against human fibrinogen, directed against 2 different fragments of this antigen]. C R Acad Sci Hebd Seances Acad Sci D (1973) 276(2):243-5.
26. Jerne NK, Roland J, Cazenave PA. Recurrent idiotopes and internal images. EMBO J (1982) 1(2):243-7.
27. Huang JH, Ward RE, Kohler H. Idiotope antigens (Ab2 alpha and Ab2 beta) can induce in vitro B cell proliferation and antibody production. J Immunol (1986) 137(3):770-6.
28. Kohler H, McNamara M, Ward RE. Idiotypes as internal antigens. Prog Clin Biol Res (1985) 172B:343-53.
29. Muller S, Wang HT, Kaveri SV, Chattopadhyay S, Kohler H. Generation and specificity of monoclonal anti-idiotypic antibodies against human HIV-specific antibodies. I. Cross-reacting idiotopes are expressed in subpopulations of HIV-infected individuals. J Immunol (1991) 147(3):933-41.
30. Parsons MS, Muller S, Kohler H, Grant MD, Bernard NF. On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development? Hum Vaccin Immunother (2013) 9(7):1532-8. doi:10.4161/hv.24460.
31. Fung J, Kohler H. Late clonal selection and expansion of the TEPC-15 germ-line specificity. J Exp Med (1980) 152(5):1262-73. doi:10.1084/jem.152.5.1262.
32. Etlinger HM, Heusser CH. T15 dominance in BALB/c mice is not controlled by environmental factors. J Immunol (1986) 136(6):1988-91.
33. Halpern R, Kaveri SV, Kohler H. Human anti-phosphorylcholine antibodies share idiotopes and are self-binding. J Clin Invest (1991) 88(2):476-82. doi:10.1172/JCI115328.
34. Kaveri SV, Halpern R, Kang CY, Kohler H. Self-binding antibodies (autobodies) form specific complexes in solution. J Immunol (1990) 145(8):2533-8.
35. Kang CY, Brunck TK, Kieber-Emmons T, Blalock JE, Kohler H. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science (1988) 240(4855):1034-6. doi:10.1126/science.3368787.
36. Kang CY, Cheng HL, RudikoffS, Kohler H. Idiotypic self binding of a dominant germline idiotype (T15). Autobody activity is affected by antibody valency. J Exp Med (1987) 165(5):1332-43. doi:10.1084/jem.165.5.1332.
37. Kang CY, Kohler H. Immunoglobulin with complementary paratope and idiotope. J Exp Med (1986) 163(4):787-96. doi:10.1084/jem.163.4.787.
38. Kohler H. Discovery of homophilic antibodies as novel drugs. Curr Trends Immunol (2009) 10:113-8.
39. Kaveri SV, Halpern R, Kang CY, Kohler H. Antibodies of different specificities are self-binding: implication for antibody diversity. Mol Immunol (1991) 28(7):773-8. doi:10.1016/0161-5890(91)90120-9.
40. Russ M, Lou D, Kohler H. Photo-activated affinity-site cross-linking of antibodies using tryptophan containing peptides. J Immunol Methods (2005) 304(1-2):100-6. doi:10.1016/j.jim.2005.06.020.
41. Kaveri SV, Kang CY, Kohler H. Natural mouse and human antibodies bind to a peptide derived from a germline VH chain. Evidence for evolutionary conserved self-binding locus. J Immunol (1990) 145(12):4207-13.
42. Briles DE, Forman C, Hudak S, Claflin JL. The effects of idiotype on the ability of IgG1 anti-phosphorylcholine antibodies to protect mice from fatal infection with Streptococcus pneumoniae. Eur J Immunol (1984) 14(11):1027-30. doi:10.1002/eji.1830141112.
43. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest (2000) 105(12):1731-40. doi:10.1172/JCI8472.
44. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol (2007) 50(6):540-6. doi:10.1016/j.jacc.2006.11.054.
45. Bingaman MG, Basu GD, Golding TC, Chong SK, Lassen AJ, Kindt TJ, et al. The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis. Anticancer Drugs (2010) 21(5):532-42. doi:10.1097/CAD.0b013e328337d485.
46. Kohler H. Homophilic antibodies as immunotherapeutics. Immunotherapy (2013) 5(3):235-46. doi:10.2217/imt.12.159.
47. Shaw PX, Goodyear CS, Chang MK, Witztum JL, Silverman GJ. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J Immunol (2003) 170(12):6151-7. doi:10.4049/jimmunol.170.12.6151.
48. Silverman GJ. Targeting of B cells in SLE: rationale and therapeutic opportunities. Bull NYU Hosp Jt Dis (2006) 64(1-2):51-6.
49. Porcheray F, Fraser JW, Gao B, McColl A, DeVito J, Dargon I, et al. Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement. Am J Transplant (2013) 13(10):2590-600. doi:10.1111/ajt.12394.
50. Ravindranath MH, Terasaki PI, Maehara CY, Jucaud V, Kawakita S, Pham T, et al. Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera. Clin Exp Immunol (2015) 179(2):309-28. doi:10.1111/cei.12450.
51. Binder M, Muller F, Frick M, Wehr C, Simon F, Leistler B, et al. CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood (2013) 121(1):239-41. doi:10.1182/blood-2012-09-454439.
52. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature (2012) 489(7415):309-12. doi:10.1038/nature11309.
53. Bryan AJ, Kohler H. Physical and biological properties of homophilic therapeutic antibodies. Cancer Immunol Immunother (2011) 60(4):507-14. doi:10.1007/s00262-010-0952-8.
54. Kohler H, Bryan AJ. Paradoxical concentration effect of a homodimerizing antibody against a human non-small cell lung cancer cell line. Cancer Immunol Immunother (2009) 58(5):749-58. doi:10.1007/s00262-008-0597-z.
55. Bona CA, Kang CY, Kohler H, Monestier M. Epibody: the image of the network created by a single antibody. Immunol Rev (1986) 90:115-27. doi:10.1111/j.1600-065X.1986.tb01480.x.
56. Urbain J, Tasiaux N, Leuwenkroon R, Van Acker A, Mariame B. Sharing of idiotypic specificities between different antibody populations from an individual rabbit. Eur J Immunol (1975) 5(8):570-5. doi:10.1002/eji.1830050813.
57. Wang QL, Wang HT, Blalock E, Muller S, Kohler H. Identification of an idiotypic peptide recognized by autoantibodies in human immunodeficiency virus-1-infected individuals. J Clin Invest (1995) 96(2):775-80. doi:10.1172/JCI118122.
58. Muller S, Margolin DH, Nara PL, Alvord WG, Kohler H. Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques. Proc Natl Acad Sci U S A (1998) 95(1):276-81. doi:10.1073/pnas.95.1.276.
59. Wallick S, Claflin JL, Briles DE. Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. J Immunol (1983) 130(6):2871-5.
60. Wang H, Muller S, Zolla-Pazner S, Kohler H. Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur J Immunol (1992) 22(7):1749-55. doi:10.1002/eji.1830220713.
61. Grant MD. Antibody convergence along a common idiotypic axis in immunodeficiency virus and hepatitis C virus infections. J Med Virol (2002) 66(1):13-21. doi:10.1002/jmv.2105.
62. Parsons MS, Rouleau D, Routy JP, LeBlanc R, Grant MD, Bernard NF. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. AIDS (2011) 25(10):1249-64. doi:10.1097/QAD.0b013e328347f9fa.
63. Gonen S, DiMaio F, Gonen T, Baker D. Design of ordered two-dimensional arrays mediated by noncovalent protein-protein interfaces. Science (2015) 348(6241):1365-8. doi:10.1126/science.aaa9897.
64. Holmberg D, Forsgren S, Ivars F, Coutinho A. Reactions among IgM antibodies derived from normal, neonatal mice. Eur J Immunol (1984) 14(5):435-41. doi:10.1002/eji.1830140510.
65. Kohler H. Novel vaccine concept based on back-boost effect in viral infection. Vaccine (2015) 33(29):3274-5. doi:10.1016/j.vaccine.2015.05.035.
66. Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, et al. HIV-1 Vaccines. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science (2015) 349(6244):156-61. doi:10.1126/science.aac5894.